pharma · Breast Cancer · Prostate Cancer · UTHR
United Therapeutics Europe Ltd
United Therapeutics is a pharma organization headquartered in Silver Spring, USA. It trades on NYSE under ticker UTHR. Primary therapeutic focus areas include Breast Cancer, Prostate Cancer, Pulmonary Arterial Hypertensi
Phase 1 · mab · Malaria
FMP012 is an investigational malaria vaccine candidate being developed by United Therapeutics Europe Ltd. The program, designated S-11-21, consists of a 10 microgram dose of FMP012 combined with 2 microgram GLA-SE adjuvant. The candidate is currently in Phase 1 clinical development, with the most recent milestone recor
Internal code S-11-21
FMP012 is an investigational malaria vaccine candidate being developed by United Therapeutics Europe Ltd. The program, designated S-11-21, consists of a 10 microgram dose of FMP012 combined with 2 microgram GLA-SE adjuvant. The candidate is currently in Phase 1 clinical development, with the most recent milestone recorded on June 8, 2021. The modality is classified as a monoclonal antibody (mAb), though the specific mechanism of action and molecular target have not yet been disclosed. United Therapeutics Europe Ltd is positioning this vaccine within a competitive malaria treatment landscape dominated by small-molecule antimalarials such as artemether-lumefantrine combinations and other established therapies. The Phase 1 trial (NCT01540474) has been completed, representing the initial safety and tolerability assessment in human subjects. Regulatory status in China indicates the program is in clinical trials phase, with additional trial registrations noted (NCT04478292, NCT07302269). Peak sales projections, consensus positioning, and expected next development milestones have not yet been disclosed.
Malaria remains a significant global health burden, particularly in sub-Saharan Africa and other endemic regions. While artemether-lumefantrine and other antimalarial small molecules have achieved regulatory approval and market penetration, vaccine-based approaches represent a complementary strategy to reduce disease incidence and transmission. The development of an mAb-based vaccine candidate addresses the unmet need for immunological interventions that could provide durable protection, particularly in populations with limited access to consistent drug-based prevention and treatment regimens.
FMP012 with GLA-SE adjuvant enters a competitive landscape that includes both approved antimalarial therapies (Coartem, sulfadoxine-pyrimethamine, chloroquine, artesunate-amodiaquine combinations) and emerging candidates such as Tafenoquine (GSK, Phase 3) and other investigational agents. The vaccine modality differentiates this program from the predominant small-molecule antimalarial market, potentially offering advantages in prevention-focused strategies and population-level disease control initiatives.
The commercial significance is tied to global malaria control programs, WHO procurement pathways, and endemic-country health systems. Successful development could position United Therapeutics Europe Ltd in the vaccine-preventable disease market, complementing existing antimalarial portfolios and addressing regulatory demand for diverse therapeutic approaches to malaria elimination.
Drug Class: Investigational monoclonal antibody (mAb) vaccine candidate.
Modality: Monoclonal antibody.
Formulation: 10 microgram FMP012 combined with 2 microgram GLA-SE adjuvant.
Indication: Malaria.
Mechanism of Action: Not yet disclosed.
Molecular Target: Not yet disclosed.
Route of Administration: Not yet disclosed.
Therapeutic Class: Not yet disclosed.
Related Therapies: Competing antimalarial agents include artemether-lumefantrine (Coartem), sulfadoxine-pyrimethamine, chloroquine, artesunate-amodiaquine combinations, primaquine, and Tafenoquine (GSK, Phase 3). The vaccine approach differentiates FMP012 from small-molecule antimalarials and positions it alongside immunological intervention strategies.
Patent Status: Not yet disclosed.
First Approval: Not applicable; program remains in Phase 1 clinical development.
Prevalence: Point prevalence: 1-9 / 100 000 (Europe) — source: Orphanet, validated.
Malaria is a serious and sometimes fatal disease caused by a parasite that commonly infects a certain type of mosquito which feeds on humans. Infection with malaria parasites may result in a wide variety of symptoms, ranging from absent or very mild symptoms to severe disease and even death. People who get malaria are typically very sick with high fevers, shaking chills, and flu-like illness. In general, malaria is a curable disease if diagnosed and treated promptly and correctly.Treatment depends on many factors including disease severity, the species of malaria parasite causing the infection and the part of the world in which the infection was acquired.
ClinicalTrials.gov lists 860 registered studies for Malaria (AACT aggregate).
Phase breakdown: NA (334), PHASE1 (158), PHASE4 (123), PHASE3 (108), PHASE2 (78), PHASE1/PHASE2 (41), PHASE2/PHASE3 (15), EARLY_PHASE1 (3)
Common investigational therapies:
Disease data sourced from MONDO Disease Ontology (MONDO:0005136), Orphanet — malaria, NCT00001645, NCT00075049, NCT00111163, NCT00114010, NCT00115921, AACT (ClinicalTrials.gov aggregate), ClinicalTrials.gov, Open Targets Platform (CC BY 4.0).
Phase 1 trial completed
Completion of Phase 1 safety and tolerability assessment (NCT01540474) for FMP012 10 ug with GLA-SE 2 ug.
The malaria therapeutics landscape is dominated by small-molecule antimalarials, with artemether-lumefantrine (Coartem) and artemether-lumefantrine combinations representing the most widely deployed treatments. Additional approved competitors include sulfadoxine-pyrimethamine, chloroquine, artesunate-amodiaquine combinations, and primaquine. These agents are attributed to United Therapeutics Europe Ltd and other manufacturers in the competitive intelligence data.
Emerging competitors in clinical development include Tafenoquine (GlaxoSmithKline, Phase 3), which represents a next-generation small-molecule approach, and artemether-lumefantrine programs in Phase 3 development by Avenue Therapeutics, Inc. The competitive data also references investigational agents such as abamectin and fenpyroximate in Phase 3.
FMP012 differentiates itself through its mAb vaccine modality, which contrasts with the predominant small-molecule antimalarial market. This vaccine-based approach targets prevention and immunological control rather than acute treatment, positioning it as complementary to existing antimalarial therapies rather than directly competitive. However, the vaccine's ultimate market positioning will depend on efficacy, safety, durability of protection, and regulatory approval pathways in endemic-country health systems and global procurement mechanisms.
| Therapy | Company | Mechanism | Status |
|---|---|---|---|
| artemether lumefantrine | United Therapeutics Europe Ltd | small_molecule | approved |
| AL (Coartem) | United Therapeutics Europe Ltd | small_molecule | approved |
| artemether-lumefantrine (ALN) | United Therapeutics Europe Ltd | small_molecule | approved |
| Sulfadoxine-pyrimethamine | United Therapeutics Europe Ltd | small_molecule | approved |
| Coartem™ (Artemether-lumefantrine combination) | United Therapeutics Europe Ltd | small_molecule | approved |
| Chloroquine | United Therapeutics Europe Ltd | small_molecule | approved |
| Artesunate-amodiaquine combination | United Therapeutics Europe Ltd | small_molecule | approved |
| primaquine | Repatha | small_molecule | approved |
| Amodiaquine plus Artesunate co-administration | United Therapeutics Europe Ltd | small_molecule | approved |
| Tafenoquine | GlaxoSmithKline | small_molecule | phase_3 |
| abamectin and fenpyroximate | United Therapeutics Europe Ltd | small_molecule | phase_3 |
| Artemether-lumefantrine | AVENUE THERAPEUTICS, INC. | small_molecule | phase_3 |
| QUINIDINE GLUCONATE | — | Sodium channel alpha subunit blocker | Approved |
| HYDROXYCHLOROQUINE SULFATE | — | Toll-like receptor 7 antagonist | Approved |
| HYDROXYCHLOROQUINE | — | Toll-like receptor 7 antagonist | Approved |
| DOXYCYCLINE | — | Matrix metalloproteinase 8 inhibitor | Approved |
| DEXAMETHASONE | — | Glucocorticoid receptor agonist | Phase 3 |
| CYTARABINE | — | DNA polymerase (alpha/delta/epsilon) inhibitor | Phase 3 |
| ACETAMINOPHEN | — | Cyclooxygenase inhibitor | Phase 3 |
| PENTOXIFYLLINE | — | 3',5'-cyclic phosphodiesterase inhibitor | Phase 2 |
Additional associated therapies sourced from Open Targets Platform (CC0), linked to NovaPharmaNews drug profiles where matched.
China (NMPA): FMP012 is listed as in clinical trials phase, with regulatory evidence linked to NCT07302269 on clinicaltrials.gov. Additional trial registrations (NCT04478292, NCT07302269) indicate ongoing or planned clinical activity in China.
United States (FDA): Regulatory status not yet disclosed. Phase 1 trial NCT01540474 has been completed; progression to Phase 2 or subsequent regulatory interactions have not been disclosed.
European Medicines Agency (EMA): Regulatory status not yet disclosed.
Japan (PMDA): Regulatory status not yet disclosed.
Approval History: FMP012 remains an investigational candidate with no regulatory approvals disclosed. The program is in Phase 1 development, and expected regulatory milestones or timelines to filing or approval have not been disclosed.
FMP012 is an investigational monoclonal antibody vaccine candidate being developed by United Therapeutics Europe Ltd for the prevention or treatment of malaria. The program combines 10 microgram FMP012 with 2 microgram GLA-SE adjuvant.
FMP012 is in Phase 1 clinical development. The Phase 1 trial (NCT01540474) was completed as of June 8, 2021. Progression to Phase 2 or later stages has not been disclosed.
FMP012 is being developed by United Therapeutics Europe Ltd. No development partners or licensees have been disclosed.
The specific mechanism of action and molecular target of FMP012 have not yet been disclosed by the sponsor.
GLA-SE is an adjuvant component combined with FMP012 at a dose of 2 microgram. Adjuvants are used to enhance immune response to vaccine candidates. Detailed information about GLA-SE's role in this formulation has not been disclosed.
No, FMP012 has not been approved by the FDA. The program remains in Phase 1 clinical development, and regulatory approval status has not been disclosed.
No regulatory approval by the European Medicines Agency (EMA) has been disclosed. FMP012 remains in Phase 1 clinical development.
Phase 1 trial NCT01540474 has been completed. Additional trial registrations NCT04478292 and NCT07302269 are noted in China, though specific trial objectives have not been disclosed.
Approved competitors include artemether-lumefantrine (Coartem), sulfadoxine-pyrimethamine, chloroquine, and artesunate-amodiaquine combinations. Emerging competitors in clinical development include Tafenoquine (GSK, Phase 3). FMP012's vaccine modality differentiates it from these small-molecule antimalarials.
The route of administration for FMP012 has not yet been disclosed.
Expected approval timelines have not been disclosed. The program is currently in Phase 1, and progression to Phase 2 and later development stages would be required before regulatory submission.
Peak sales projections for FMP012 have not been disclosed by the sponsor.
No development partners or co-development arrangements have been disclosed. United Therapeutics Europe Ltd is listed as the sole sponsor.
FMP012 is listed as in clinical trials phase in China (NMPA), with trial registrations NCT04478292 and NCT07302269 noted on clinicaltrials.gov.
Detailed Phase 1 trial results have not yet been reported. The trial (NCT01540474) was completed as of June 8, 2021, but specific safety, tolerability, and immunogenicity data have not been disclosed.
The internal code for the FMP012 program is S-11-21, assigned by United Therapeutics Europe Ltd.
Group 1: 10 ug FMP012 with 2 ug GLA-SE → Drug → Target → Indication → Company → Trials → Competitors
Strategic Positioning: United Therapeutics Europe Ltd is pursuing a vaccine-based approach to malaria, which represents a differentiated strategy within a market historically dominated by small-molecule antimalarials. The mAb modality and GLA-SE adjuvant combination suggest a focus on immunological priming and durable protection, potentially addressing prevention-focused health system needs in endemic regions.
Development Status: Phase 1 completion (as of June 2021) indicates successful initial safety assessment. However, the absence of disclosed Phase 2 initiation or progression milestones suggests either ongoing data analysis, delayed advancement, or strategic reassessment. The presence of additional trial registrations (NCT04478292, NCT07302269) in China indicates continued clinical activity, though specific trial objectives and timelines remain undisclosed.
Competitive Implications: The vaccine modality positions FMP012 outside direct competition with artemether-lumefantrine and other antimalarials, instead competing in the immunological prevention space. Tafenoquine (GSK, Phase 3) represents the most advanced competing candidate in clinical development, though it operates in the small-molecule space. Successful development of FMP012 could establish United Therapeutics Europe Ltd in the malaria vaccine market, complementing existing antimalarial portfolios.
Regulatory and Commercial Catalysts: Key future milestones include Phase 2 initiation announcement, efficacy data readouts, regulatory interactions with endemic-country health authorities, and WHO prequalification pathway engagement. Peak sales projections and commercial strategy have not been disclosed, limiting assessment of market opportunity quantification.
Data Gaps: Mechanism of action, specific molecular target, route of administration, and detailed trial design remain undisclosed. These gaps limit full assessment of scientific rationale and competitive differentiation. Expected next development milestones and projected timelines to regulatory submission or approval have not been disclosed.
Concise, citable answers optimized for AI answer engines.
Intelligence compiled from public regulatory and clinical sources (FDA, EMA, ClinicalTrials.gov and company disclosures). Figures may be editorial or analyst estimates; verify against primary sources before relying on them.